Abstracting and indexing is one of those quiet pieces of scientific infrastructure that most readers never think about, yet it determines nearly everything about how research travels. When a journal is indexed in a major database, every article it publishes is given a standardized bibliographic record, complete with authors, affiliations, keywords, and a persistent identifier, that can be retrieved by search engines, discovery platforms, and citation-tracking systems. Without that record, even excellent research risks becoming effectively invisible, buried in a journal that databases do not scan. Inclusion in the Science Citation Index Expanded, maintained as part of the Web of Science family of databases, is therefore a mark of editorial quality control and a practical guarantee that a journal’s output will be findable by the global research community.

The Science Citation Index Expanded has a long history as one of the core citation indexes in science. It covers thousands of journals across the natural sciences, engineering, medicine, and related disciplines, and its selection process is deliberately selective. Journals are evaluated on publishing standards, editorial rigor, international diversity of authorship and editorial boards, citation behavior, peer-review integrity, and the overall usefulness of the content to the research community. For a journal to be admitted, and then to remain, in the index requires sustained performance against those criteria. The Journal of Pharmaceutical Investigation’s entry into the index in 2021 marked the point at which its articles began accumulating formal citation records in the Web of Science ecosystem, the raw material from which metrics such as the Impact Factor are later computed.

That leads directly to the second and more widely discussed number: the 5.5 Impact Factor recorded for 2022. The Journal Impact Factor, produced annually in the Journal Citation Reports, is calculated by counting citations in a given year to items published in the journal during the two preceding years, then dividing by the number of citable items, typically articles and reviews, published in those same two years. A 2022 Impact Factor of 5.5 therefore reflects the average number of times that 2020 and 2021 articles in the journal were cited during 2022. It is a two-year citation window, which makes the metric sensitive to recent momentum and to fields where citation practices are fast-moving, as pharmaceutical research very much is.

Context matters enormously when interpreting that figure. A raw Impact Factor of 5.5 means little until it is compared against other journals in the same field, which is exactly what the category ranking provides. In Pharmacology and Pharmacy, a broad and heavily populated category with 278 indexed journals, the Journal of Pharmaceutical Investigation ranked 48th, placing it in the top quartile, or Q1. Quartile designations divide each category into four bands, and Q1 status is commonly used by libraries, funding agencies, and university evaluation committees as a shorthand for a journal sitting among the most influential quarter of titles in its discipline. For a journal that only entered the index in 2021, reaching Q1 within roughly two years of eligibility represents a notably rapid climb.

The mechanics behind that climb are worth understanding, because they illustrate how citation dynamics work in pharmaceutical research. Journals in this field benefit from several structural advantages: pharmaceutical science sits at the intersection of chemistry, biology, pharmacology, and clinical medicine, so articles tend to be cited from many neighboring disciplines rather than a single narrow community. Drug delivery technologies, formulation science, pharmacokinetics, and nanomedicine are all areas of intense global activity, and work published in these areas is frequently referenced in patents, review articles, and follow-up experimental studies. A journal that successfully attracts strong submissions in these active areas can accumulate citations quickly, and the two-year Impact Factor window rewards exactly that kind of momentum.

At the same time, the pharmaceutical research community has been vocal in recent years about the limits of single-number metrics, and any reading of the new figures should acknowledge those debates. The Impact Factor does not distinguish between a highly cited review and a routine research article, it can be influenced by a small number of exceptionally cited papers, and it says nothing about the methodological quality or reproducibility of individual studies. Initiatives such as the Declaration on Research Assessment, known as DORA, have urged institutions to move away from journal-level metrics when judging individual researchers, favoring article-level measures and qualitative expert review instead. The Journal of Pharmaceutical Investigation’s Q1 ranking is best understood as one signal among several, indicating broad visibility and citation uptake rather than certifying the quality of any specific paper.

For authors deciding where to submit, indexing status and quartile rankings still carry practical weight. Many national funding bodies and promotion committees maintain lists of acceptable journals built directly on Web of Science indexing and quartile positions, and some require publication in Q1 or Q2 titles for grant eligibility or degree completion. Indexing in the Science Citation Index Expanded also ensures that articles are preserved and discoverable through institutional libraries worldwide, which affects readership and, indirectly, future collaboration opportunities. In this sense, the journal’s documented indexing record and its 2022 metrics function as a form of infrastructure: they lower the friction between a published finding and the researcher who needs it.

What happens next will depend on the journal’s continued editorial performance. Impact Factors are recalculated every year, and quartile boundaries shift as competing journals rise and fall, so the 48th-of-278 position is a snapshot rather than a permanent achievement. Journals that sustain rigorous peer review, publish timely special issues in fast-moving areas such as biologics, drug delivery systems, and personalized pharmacotherapy, and maintain transparent editorial practices tend to hold their positions, while those that do not can slip quickly in a category as crowded as Pharmacology and Pharmacy. For now, the published record is clear: indexed in SciSearch since 2021, an Impact Factor of 5.5 in 2022, and a Q1 ranking within one of pharmacology’s largest and most competitive categories, a combination that firmly establishes the Journal of Pharmaceutical Investigation among the visible and influential outlets for pharmaceutical research.

Subject of Research: Indexing status and 2022 Impact Factor performance of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, abstracting and indexing, Science Citation Index Expanded, SciSearch, Impact Factor, Journal Citation Reports, Pharmacology and Pharmacy, Q1 ranking, Web of Science, citation metrics, scholarly publishing, journal ranking

To understand why indexing in Science Citation Index Expanded carries such weight, it helps to consider what the database actually represents. Maintained by Clarivate, the Science Citation Index Expanded is one of the core components of the Web of Science, the citation ecosystem that underpins the Journal Impact Factor, one of the most scrutinized metrics in academic publishing. Journals are not simply admitted to the index; they must pass through a rigorous evaluation process that examines editorial rigor, publishing timeliness, international diversity among authors and editors, citation behavior, and the overall scholarly contribution of the published work. Inclusion signals to researchers that a journal has met internationally recognized standards of quality and that its articles will be discoverable, citable, and counted in the citation networks that shape modern scientific communication.

The timing of the journal’s admission matters as well. Coverage beginning in 2021 means that articles published from that year onward are tracked in the index, allowing citations to accumulate and, after the standard waiting period, contributing to the Impact Factor calculations released annually. The 2022 Impact Factor of 5.5 reflects the frequency with which articles published in 2020 and 2021 were cited during 2022, normalized across the number of substantive research items the journal published in that window. A value of 5.5 is a strong result in pharmacology, a field where citation patterns are often concentrated in a small number of high-profile journals. Reaching a figure of this magnitude shortly after entering the index is notable, because new entrants typically take several years to build the citation base needed for competitive Impact Factors.

Equally significant is the journal’s position within its category. The Web of Science ranks journals in each subject category both by raw Impact Factor and by percentile, dividing them into quartiles designated Q1 through Q4. Ranking 48th out of 278 journals in Pharmacology and Pharmacy places the Journal of Pharmaceutical Investigation in Q1, the top quartile, roughly the top 17 percent of journals in the category. Many universities, funding agencies, and research assessment exercises treat Q1 status as a benchmark of excellence, and publishing in Q1 journals can influence hiring decisions, grant evaluations, and institutional rankings. For authors weighing where to submit their work, the combination of indexing, a healthy Impact Factor, and Q1 ranking makes the journal a considerably more attractive destination than it was before these achievements.

The mechanics behind these numbers deserve a closer look, because they illuminate how scientific reputation is quantified. The Impact Factor, despite its limitations and the ongoing debate about the role it should play in research assessment, remains the single most requested journal metric worldwide. It is computed by dividing the number of citations in a given year to items published in the journal during the preceding two years by the number of citable items, typically articles and reviews, published in those same two years. Distinguishing between citable and non-citable items, such as editorials, letters, and news pieces, is a frequent source of confusion and contention, but the underlying idea is straightforward: the metric aims to capture the average annual citation rate of a journal’s core scholarly output. A journal that publishes clinically and scientifically relevant work in drug development, formulation, pharmacokinetics, and therapeutic evaluation tends to attract steady citation attention from both academic and industry-affiliated researchers.

For the pharmaceutical research community specifically, the value of robust indexing extends beyond prestige metrics. Pharmaceutics and pharmacology are deeply interdisciplinary fields in which academic laboratories, hospital pharmacists, regulatory scientists, and industrial researchers all draw on the same literature. When a journal is comprehensively indexed in Science Citation Index Expanded, its articles become systematically searchable through Web of Science interfaces and through the many discovery platforms that build on its data. Systematic reviews, meta-analyses, and evidence syntheses, all of which are central to evidence-based pharmacotherapy, depend on comprehensive retrieval of relevant studies. Gaps in indexing can mean that important research is overlooked in these syntheses, so broad coverage benefits not just the journal but the accuracy and completeness of the scientific record as a whole.

The journal’s subject scope explains much of its appeal to contributors and readers. Publications of this kind typically cover investigations spanning drug delivery systems, pharmacokinetics and pharmacodynamics, clinical pharmacy practice, pharmaceutical technology, and therapeutic outcomes, providing a venue for work that bridges laboratory formulation science and clinical application. Research of this type sits at the intersection of chemistry, biology, medicine, and engineering, and its readership spans hospital pharmacies, academic departments of pharmaceutics, regulatory bodies, and pharmaceutical companies. A journal serving such a broad community has a strong incentive to maximize discoverability, since potential authors and readers are distributed across many countries and many professional settings. Indexing in the major citation databases is the most direct route to that visibility, and the Q1 ranking now makes the journal competitive for submissions that might previously have gone to longer-established titles.

It is also worth situating this achievement within broader trends in scholarly publishing. The pharmaceutical sciences have expanded dramatically over the past two decades, driven by biologics, novel drug delivery platforms, nanomedicine, and the growing importance of pharmacoeconomics and health outcomes research. This expansion has multiplied the number of journals competing for high-quality submissions, intensifying pressure on editors to demonstrate quality through metrics. At the same time, the research community and major funders have increasingly questioned overreliance on the Impact Factor, promoting alternatives such as article-level citation measures, preprint visibility, and responsible research assessment frameworks. Even so, indexing status and quartile rankings continue to function as practical gatekeepers in the day-to-day decisions of authors, librarians, and evaluators, which is why a journal’s successful entry into the Science Citation Index Expanded and its attainment of Q1 status remain genuinely newsworthy events for its community.

Looking ahead, the journal’s trajectory will depend on sustaining the editorial standards and citation performance that earned its current standing. Early Impact Factors can be volatile, and consolidating a Q1 position requires consistent publication of work that other researchers find useful and citable. If the journal maintains the quality and breadth that accompanied its 2021 indexing and its 2022 Impact Factor of 5.5, it is well positioned to strengthen its role as a reference point for pharmaceutical investigation internationally. For now, the combination of Science Citation Index Expanded coverage, a solid Impact Factor, and a top-quartile category ranking represents a clear vote of confidence from the bibliometric infrastructure that helps determine which journals the global research community reads, cites, and trusts.

Subject of Research: Abstracting and indexing of the Journal of Pharmaceutical Investigation in Science Citation Index Expanded and its 2022 Impact Factor of 5.5 with Q1 ranking in Pharmacology and Pharmacy

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Science Citation Index Expanded, SciSearch, Web of Science, Impact Factor, Q1 journal, Pharmacology and Pharmacy, journal indexing, citation metrics, pharmaceutical sciences, Clarivate, scholarly publishing

The Science Citation Index Expanded, often encountered by researchers under its search interface name SciSearch or through the Web of Science platform, functions as a comprehensive record of scholarly articles across the natural sciences, engineering, and medicine. When a journal is accepted into the index, every published article receives structured metadata — authors, affiliations, abstracts, keywords, and references — that allows the paper to be retrieved, linked, and counted. Citations flowing between indexed journals form the raw material for a family of quantitative indicators, most famously the Journal Impact Factor, that have become embedded in hiring, funding, and institutional evaluation processes around the world. Absence from the index, by contrast, can leave even high-quality research effectively invisible to large portions of the international community, particularly automated literature-discovery systems and systematic review workflows that rely on indexed databases as their primary search universe.

Following its inclusion, the Journal of Pharmaceutical Investigation recorded a Journal Impact Factor of 5.5 for 2022, a figure derived from the ratio of citations received in that year to the citable items — typically original research articles and reviews — published during the preceding two-year window. In the subject category of Pharmacology and Pharmacy, that score corresponded to a ranking of 48th out of 278 indexed journals, placing the publication in the first quartile, or Q1, of its field. Quartile position is a compressed but influential signal: it indicates that a journal sits among the top quarter of titles in its discipline by citation density, and many institutions explicitly require Q1 placement when researchers select venues for their work. For a journal that had operated for years outside the indexed core, the debut performance represents an unusually strong entry.

The mechanics behind these numbers are worth unpacking, because they explain both the value and the limitations of the metric. An impact factor of 5.5 means that, on average, each citable item published by the journal in 2020 and 2021 was cited 5.5 times in 2022 across the entire indexed literature. Review articles, which synthesize large bodies of work and are cited heavily, can inflate this average; so can a small number of highly cited papers in a small publication volume. Journal size, publication frequency, and topical timing all introduce volatility, which is why bibliometric experts consistently caution against treating the impact factor as a direct measure of the quality of any individual paper. A citation to a specific article is a vote for that article’s usefulness, not for every article sharing the same masthead. Nevertheless, at the level of journal selection — deciding where to submit, which subscriptions to fund, or which titles to trust for rapid scanning — the metric retains enormous practical weight, and a Q1 ranking in a competitive category such as Pharmacology and Pharmacy, where 278 titles compete, signals genuine traction with the research community.

The context in which this achievement occurred matters as much as the number itself. Pharmaceutical investigation as a discipline sits at a crowded crossroads: medicinal chemistry, pharmacokinetics, drug delivery, clinical pharmacology, and regulatory science all generate vast literatures, and hundreds of journals compete for the manuscripts that result. In such an environment, visibility is a scarce resource. Authors increasingly consult journal metrics before submitting, and funding agencies in many countries now ask applicants to characterize the venues in which their prior work appeared. A journal’s entry into the Science Citation Index Expanded therefore changes its competitive position in a feedback loop that can accelerate over successive years: indexing brings discoverability, discoverability brings readers and citations, citations bring higher metrics, and higher metrics attract stronger submissions, which in turn reinforce the citation profile. Editorial teams are well aware of this dynamic, which is why indexing milestones are often described within the publishing industry as inflection points rather than endpoints.

For the research community in pharmaceutical science, the practical consequences of indexing are concrete. A scientist in Seoul, São Paulo, or Stockholm running a structured literature search through Web of Science will now surface relevant articles from the journal that previously would have been missed by that particular query, even if they were retrievable through other services such as PubMed or Scopus. Systematic reviewers, who follow strict protocols requiring multi-database searching to avoid bias, can now legitimately include the journal in their source lists. Bibliometric analysts mapping collaboration networks or tracking research fronts in drug development will find its citation links woven into their datasets. Even citation managers and reference-checking tools benefit, because indexed metadata is typically cleaner and more complete than the free-text records scraped from journal websites. In short, indexing converts a journal from an isolated island of content into a node in the interconnected graph of global scholarship.

The milestone also reflects broader changes in how scholarly publishing evaluates and rewards journals. The Science Citation Index Expanded has tightened its acceptance criteria over the past decade, applying a consistent editorial standards review that examines publication ethics, peer-review rigor, editorial board composition, timeliness, and international authorship alongside raw citation performance. Journals are no longer admitted simply because they publish frequently; they must demonstrate sustainable editorial governance and adherence to the community’s ethical norms. Achieving inclusion in the 2021 cycle therefore implies that the journal passed a substantive vetting process covering both its operational practices and the scientific standing of its published content. This dual scrutiny is one reason why indexing status carries credibility with institutions that must make funding and promotion decisions without reading every paper themselves.

At the same time, the pharmaceutical sciences are undergoing a transformation that gives journals in this field unusual strategic importance. The past several years have seen unprecedented attention to drug development — from the rapid clinical evaluation of vaccines and antivirals to the rise of biologics, mRNA platforms, and precision medicine approaches tailored to molecular subtypes of disease. Each of these frontiers generates intense publication activity, and the citation metrics of journals in Pharmacology and Pharmacy have shifted accordingly, with the field’s leading titles posting some of the strongest citation growth in the biomedical sciences. A journal entering the indexed landscape during such a period inherits both opportunity and pressure: the appetite for pharmaceutical research findings is enormous, but so is the competition, and new entrants must quickly establish editorial identity — whether in translational pharmacology, formulation science, or clinical investigation — to convert visibility into durable citation performance.

Looking ahead, the trajectory of the journal will depend on factors that no single metric can fully capture. Sustaining a Q1 position requires consistent editorial output, successful attraction of high-impact submissions, and continued adherence to the standards that secured indexing in the first place. Citation databases conduct periodic re-evaluation, and titles that slip in quality or timeliness can be discontinued from coverage, a risk that keeps editorial offices accountable long after the initial acceptance. For now, however, the combination of Science Citation Index Expanded coverage and a first-quartile impact factor of 5.5 gives the Journal of Pharmaceutical Investigation the visibility infrastructure and quantitative credentials that authors, reviewers, and readers in the global pharmaceutical research community rely upon when deciding where the most consequential work in their field is being published and debated.

Subject of Research: Abstracting and indexing of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded and its Q1 impact factor in Pharmacology and Pharmacy

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Science Citation Index Expanded, Journal Impact Factor, pharmacology and pharmacy, Q1 journal ranking, abstracting and indexing, Web of Science, bibliometrics, scholarly publishing, pharmaceutical sciences, citation metrics, Clarivate Analytics

Abstracting and indexing is the process by which a journal’s published articles are systematically catalogued in major bibliographic databases, allowing them to be discovered, cited, and tracked by the global research community. Inclusion in the Science Citation Index Expanded, one of the core citation databases maintained within the Web of Science platform, signals that a journal has passed a rigorous editorial evaluation covering publishing standards, editorial board composition, peer-review integrity, international diversity of authorship, and the consistency of its scholarly output. For pharmaceutical researchers, this means that articles appearing in the journal are now fully searchable alongside the most influential literature in pharmacology and pharmacy, and that citations to those articles are counted in official journal metrics.

The Impact Factor, the most widely recognized of these metrics, is calculated by dividing the number of citations received in a given year by articles published in the two preceding years. A value of 5.5 for 2022 indicates that, on average, papers published in the journal during 2020 and 2021 were cited 5.5 times in 2022. This figure places the journal comfortably within the upper tier of its category, since quartile rankings divide the journals in a subject class into four equal groups by citation performance. A Q1 designation, corresponding to the top 25 percent of the 278 journals ranked in Pharmacology and Pharmacy, is a benchmark many institutions use when assessing publication quality for hiring, promotion, and funding decisions.

The rank of 48 out of 278 is particularly notable in a category as large and competitive as Pharmacology and Pharmacy, which spans everything from basic molecular pharmacology to clinical therapeutics and pharmaceutical manufacturing. Journals in this category compete for citations from a vast body of global research, and moving into the first quartile typically requires sustained growth in both the quality and the visibility of published work. For a journal focused specifically on pharmaceutical investigation, the achievement reflects the growing citation footprint of research on drug delivery systems, nanomedicine, pharmacokinetics, and the formulation technologies that translate laboratory discoveries into clinical products.

Indexing in SciSearch since 2021 means the journal’s metrics are still relatively young within the Web of Science ecosystem, which makes the 2022 Impact Factor an early but meaningful indicator of its trajectory. New journals often take several years to accumulate the citation history needed for stable rankings, and early Impact Factors can fluctuate as the indexed back-file grows. A first-quartile placement within roughly two years of indexing suggests that the journal’s existing body of work was already attracting substantial citations, and that its inclusion in the database made that influence visible to the evaluators, librarians, and researchers who rely on these metrics to navigate the literature.

The practical consequences of indexing and quartile performance extend well beyond prestige. Researchers choosing where to submit manuscripts frequently consult journal rankings to maximize the reach and career value of their work, and many funding agencies and universities maintain lists of approved outlets based on Web of Science categories and quartiles. Librarians use the same data to make subscription decisions. For authors in pharmaceutical sciences, a Q1 journal with a 5.5 Impact Factor offers a combination of disciplinary focus and broad discoverability that can accelerate the uptake of new methods, from controlled-release formulations to novel excipients and biopharmaceutical characterization techniques.

Bibliometric experts caution, however, that the Impact Factor is a blunt instrument. It measures average citations to a two-year window of articles and can be influenced by a small number of highly cited reviews, by the overall volume of publication, and by citation practices that vary across subfields. Pharmacology and pharmacy journals, which sit at the interface of basic science and applied medicine, often benefit from citation patterns that differ from those of purely clinical or purely basic titles. For this reason, evaluators are increasingly encouraged to read quartile rankings alongside other indicators, such as the journal’s scope, its peer-review standards, and the actual readership of individual papers rather than journal-level averages alone.

Even with those caveats, the formal recognition matters for the research community the journal serves. Pharmaceutical investigation is a field in which translational timelines are long and the path from molecular discovery to approved therapy depends on shared methodological standards. When a specialized journal achieves first-quartile status, it strengthens the visibility of the applied and formulation-oriented research that often falls between the traditional categories of pharmacology and chemical engineering. This can help ensure that advances in drug delivery technology, bioequivalence assessment, and pharmaceutical quality control receive the same citation attention as breakthroughs in target discovery or clinical trial results.

The journal’s listing with Springer, which publishes the title as part of its pharmaceutical sciences portfolio, provides the authoritative record of its indexing status and metric performance. The publisher’s announcement confirms both the 2021 start of Science Citation Index Expanded coverage and the 2022 Impact Factor of 5.5, along with the category rank of 48 out of 278 in Pharmacology and Pharmacy. These figures will be updated annually as new citation data become available, and the journal’s position will be watched by authors, editors, and bibliometric analysts alike as an indicator of how specialized pharmaceutical research titles fare in an increasingly metrics-driven publishing environment.

For the broader scientific publishing landscape, the case illustrates how abstracting and indexing functions as the gateway through which journals enter the formal economy of scholarly recognition. Without inclusion in the major citation databases, even high-quality research risks invisibility in the evaluations that shape careers and funding. With inclusion, and with a strong early Impact Factor, a journal can rapidly become a destination for the work that defines its field. The Journal of Pharmaceutical Investigation’s Q1 standing demonstrates that a focused pharmaceutical title can achieve that recognition quickly, provided its published research resonates with the citation behavior of the international pharmacology and pharmacy community.

Subject of Research: Indexing of the Journal of Pharmaceutical Investigation in Science Citation Index Expanded and its 2022 Impact Factor of 5.5 with a Q1 rank of 48/278 in Pharmacology and Pharmacy

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, abstracting and indexing, Science Citation Index Expanded, SciSearch, Impact Factor, quartile ranking, pharmacology and pharmacy, Web of Science, bibliometrics, pharmaceutical sciences, Springer, citation metrics

Abstracting and indexing services form the backbone of scientific communication infrastructure. When a journal is abstracted and indexed, its article records, including titles, author names, affiliations, abstracts and bibliographies, are systematically captured and catalogued in large bibliographic databases that researchers around the world use every day. Science Citation Index Expanded, maintained within the Web of Science platform, is one of the most selective and widely consulted of these services. Inclusion signals that a journal has passed editorial quality assessments covering peer-review rigor, publication ethics, editorial board composition, timeliness and international reach. For a pharmaceutical sciences journal, this recognition is particularly consequential because the field spans chemistry, pharmacology, formulation science, clinical investigation and regulatory science, and its researchers rely on comprehensive literature discovery to avoid duplication and build on prior findings.

The mechanics of indexing are less visible to readers but essential to how science circulates. Once a journal is accepted into SciSearch, every published article receives consistent metadata treatment: digital object identifiers are registered, citations between articles are tracked, and bibliometric algorithms can count how often a paper is referenced by later work. This citation network is what makes quantitative measures possible in the first place. Without structured indexing, citation counts would be fragmented across publisher websites and impossible to aggregate reliably. Indexed status also enables discovery through search platforms that institutions license, meaning a clinical pharmacist in Seoul or a formulation scientist in Boston encounters the journal’s content through the same trusted databases rather than through scattered web searches.

The impact factor of 5.5 reported for 2022 is calculated through a well-defined formula: it counts the citations received in that year by articles the journal published in the two preceding years, divided by the number of citable items, typically research articles and reviews, published in those same two years. A value of 5.5 means that, on average, recent articles in the journal were cited more than five times within roughly two years of publication, a strong performance in pharmacology and pharmacy, where citation patterns tend to be steadier and more gradual than in fast-moving fields such as molecular biology. The Q1 designation, derived from the journal’s position at 48 of 278 in its category, means it falls within the top quartile of titles, a threshold many institutions use as a benchmark for high-quality publication.

Within the pharmaceutical research community, these metrics carry practical weight. Journals that rank highly attract manuscripts from established laboratories, which in turn raises the technical quality and relevance of published work, creating a feedback loop of visibility and citation. For authors, publishing in an indexed, Q1-ranked journal ensures that their findings are counted in institutional assessments, grant applications and national research evaluation frameworks, many of which explicitly require Web of Science or Scopus inclusion. For readers, the ranking acts as a quality heuristic, a signal that the peer review process has historically filtered submissions with reasonable strictness. For librarians managing tight budgets, category rank and impact factor often inform subscription and renewal decisions, so a journal’s bibliometric performance directly shapes whether researchers can access it at all.

The journal’s subject area itself explains why this recognition resonates. Pharmaceutical investigation encompasses preclinical drug evaluation, pharmacokinetics and pharmacodynamics, novel delivery systems, nanotechnology-based formulations, biopharmaceutics and translational research linking laboratory findings to clinical outcomes. This is a domain where the pace of innovation is accelerating, driven by biologics, RNA therapeutics, targeted delivery platforms and computational drug design. Researchers in these areas depend on rapid, reliable access to peer-reviewed results, and a journal embedded in the core citation indexes effectively becomes part of the discipline’s shared memory. Articles that might otherwise remain niche become discoverable through citation chains, review articles and database alerts.

Entry into Science Citation Index Expanded in 2021 marked a milestone because that year is the starting point from which the journal’s citation record accumulates in the index. Impact factors for newly indexed journals require a lag period before the citation window contains sufficient data, so the 5.5 figure for 2022 represents the first full measurement of the journal’s citation performance within the service. Achieving a Q1 rank in that early measurement window is notable, since it indicates that work published in the journal was already being cited at a level competitive with long-established titles in pharmacology and pharmacy. It also suggests that the journal’s editorial scope aligns with active research fronts where citation activity is naturally concentrated.

Bibliometric indicators should nevertheless be read with nuance, a point widely acknowledged across the scholarly communication community. An impact factor describes the average citation behavior of a journal’s recent output, not the quality of any individual article, and citation counts vary by article type, topic popularity and review share. A journal publishing influential methodological reviews may see its average lifted relative to one focused on narrow empirical studies. Category rankings are more robust because they compare journals within the same discipline, but they still aggregate across subfields with different citation customs. Researchers and evaluators are therefore encouraged to treat the 5.5 impact factor and Q1 rank as one signal among several, alongside peer review reports, replication records and the actual content of the research itself.

For the journal’s editorial team, sustained indexing brings ongoing obligations. Indexed journals must maintain consistent publication schedules, transparent peer review workflows, correctable article records and adherence to publishing ethics standards. Data integrity, authorship transparency and conflict-of-interest disclosure are scrutinized both at submission and in periodic re-evaluation by indexing services, which can delist journals that fall short. This accountability framework benefits the entire pharmaceutical sciences community: it keeps the citation record trustworthy, ensures that meta-analyses and systematic reviews rest on verifiable sources, and protects early-career researchers who stake their careers on publications whose provenance must withstand institutional scrutiny.

As pharmaceutical research grows more interdisciplinary, the role of well-indexed journals as connective tissue between chemistry, biology, engineering and clinical medicine will only expand. The Journal of Pharmaceutical Investigation’s presence in Science Citation Index Expanded since 2021, combined with its 2022 impact factor of 5.5 and its Q1 standing at 48 of 278 in Pharmacology and Pharmacy, positions it as a reference point for researchers navigating this crowded landscape. Whether these metrics translate into durable scientific influence depends on the quality of the work the journal continues to publish and the rigor of its editorial processes, but the early indicators suggest that its articles are reaching the audiences positioned to build on them, cite them and, ultimately, convert them into better medicines.

Subject of Research: Abstracting, indexing and citation performance of the Journal of Pharmaceutical Investigation in Web of Science and pharmacology journal rankings

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, abstracting and indexing, Science Citation Index Expanded, SciSearch, Web of Science, impact factor, Q1 journal, Pharmacology and Pharmacy, pharmaceutical sciences, bibliometrics, scholarly publishing, citation metrics

Abstracting and indexing, often abbreviated as A&I, is the process by which bibliographic databases catalog scholarly articles, capturing their titles, authors, abstracts, keywords and citations in structured records that can be searched, sorted and analyzed at scale. For researchers, these databases are the primary discovery tools of modern science: a paper that is not indexed in the major services is effectively invisible to most of the global research community, no matter how rigorous its methods or how significant its findings. For journals, inclusion in prestigious indexes is both a badge of quality and a practical necessity, because libraries, funders and tenure committees routinely evaluate publications based on where they are indexed and what citation metrics those indexes generate.

The Journal of Pharmaceutical Investigation has been abstracted and indexed in the Science Citation Index Expanded, commonly known as SciSearch, since 2021. The Science Citation Index Expanded is maintained by Clarivate as part of the Web of Science platform, one of the most authoritative citation databases in the world. It traces its lineage to the original Science Citation Index created by Eugene Garfield in the 1960s, a pioneering effort to map the flow of ideas through the scientific literature by tracking which papers cite which. That citation network remains the foundation of modern bibliometrics, and inclusion in the expanded index signals that a journal has passed a rigorous editorial evaluation covering publishing standards, editorial content, international diversity and citation behavior.

Once a journal is indexed in the Science Citation Index Expanded, it becomes eligible for the Journal Impact Factor, the single most widely cited metric in scholarly publishing. The impact factor is calculated by dividing the number of citations received in a given year by items published in the journal during the two preceding years. A journal’s 2022 impact factor of 5.5 therefore means that, on average, articles published in 2020 and 2021 were cited 5.5 times each during 2022. While the metric has well-documented limitations, it remains a shorthand that researchers, institutions and publishers watch closely, and movement in the rankings can shape manuscript submission patterns, editorial strategies and even national research assessment frameworks.

A ranking of 48 out of 278 journals places the Journal of Pharmaceutical Investigation in the first quartile, or Q1, of the Pharmacology and Pharmacy category, meaning it sits among the top 25 percent of titles in its field. Quartile rankings are derived by ordering journals within a category by impact factor and dividing them into four equal bands. Q1 status is particularly meaningful in pharmacology, one of the most competitive categories in the Web of Science, where established titles with decades of history and enormous submission volumes compete for citation attention. For a journal to reach and hold a Q1 position, its published work must not only meet high editorial standards but also resonate with a broad community of researchers who choose to cite it in their own studies.

The journal’s subject matter helps explain that resonance. Pharmaceutical investigation encompasses the entire lifecycle of a drug, from early discovery and formulation science through pharmacokinetics, pharmacodynamics, clinical evaluation, manufacturing quality and post-marketing surveillance. Research in this space is inherently translational, connecting laboratory findings to therapeutic outcomes, and it draws citations from a wide range of adjacent disciplines, including biotechnology, nanomedicine, regulatory affairs and clinical pharmacy. Journals that publish work spanning this breadth tend to accumulate citations from many communities, which strengthens their bibliometric performance and, in a self-reinforcing loop, attracts further high-quality submissions from authors seeking visibility.

The timing of the journal’s SciSearch inclusion in 2021 and its subsequent impact factor performance illustrates a broader dynamic in scholarly publishing. New or newly indexed journals typically need two full publication cycles before their first official impact factor can be calculated, because the metric depends on a two-year citation window. The years immediately following indexing are therefore critical: editors work to commission review articles, which are disproportionately cited, and to attract original research from prominent groups, knowing that early citation performance will set the trajectory of the journal’s metrics for years to come. Achieving a 5.5 impact factor within a short period of entering the index suggests that the journal’s editorial strategy and its community of contributors have aligned effectively with the citation patterns of contemporary pharmaceutical research.

Behind the headline numbers lies an elaborate ecosystem of data infrastructure. When an article is published, its metadata are transmitted to indexing services, where they are normalized against standards for author names, affiliations, funding information and references. Citation links are then resolved and aggregated, feeding not only the impact factor but also a family of related indicators, including the five-year impact factor, the immediacy index, the cited half-life and the eigenfactor, each of which captures a different dimension of a journal’s scholarly footprint. Databases also power literature search engines, reference managers and systematic review workflows, meaning that indexing quality directly affects how efficiently science itself proceeds. Errors or gaps in indexing can delay discoveries, skew bibliometric analyses and misrepresent the provenance of ideas.

For the pharmaceutical sciences specifically, robust indexing carries practical stakes beyond prestige. Systematic reviews and meta-analyses, which underpin clinical guidelines and regulatory decisions, depend on comprehensive database coverage to identify all relevant evidence. Pharmacovigilance researchers tracking adverse events, formulation scientists surveying delivery technologies and health economists assessing drug value all rely on indexed literature to build complete pictures of the evidence base. A journal’s presence in the Science Citation Index Expanded therefore contributes to the reliability of the evidence synthesis on which drug safety and efficacy decisions ultimately rest, a responsibility that extends well beyond the publishing world into patient care.

The Journal of Pharmaceutical Investigation’s Q1 standing in 2022 is a snapshot of a competitive and rapidly evolving field, and maintaining that position will require continued editorial rigor as publishing itself changes. Preprint servers, open access mandates, alternative metrics and new assessment frameworks such as the Declaration on Research Assessment are reshaping how scholarly value is measured, and citation-based indicators are increasingly scrutinized for the ways they can be gamed or misapplied. Yet for now, the combination of SciSearch indexing and a 5.5 impact factor confirms the journal’s place among the leading venues for pharmaceutical research, offering authors a platform with global discoverability and offering readers a curated window into the science that moves molecules from the bench to the bedside.

Subject of Research: The indexing of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded and its 2022 impact factor and Q1 ranking in Pharmacology and Pharmacy

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, impact factor, abstracting and indexing, Science Citation Index Expanded, Web of Science, pharmacology, pharmacy, Q1 journal, citation metrics, pharmaceutical sciences, bibliometrics, Clarivate

Abstracting and indexing is the infrastructure that underpins the modern scientific record. When a journal is accepted into a major citation index, its articles become discoverable through the databases that scientists, clinicians, and institutions rely on every day to survey the literature. The Science Citation Index Expanded, maintained within the Web of Science platform, is one of the most selective and influential of these databases. Inclusion signals that a journal has passed rigorous editorial evaluation covering publishing standards, peer-review integrity, international editorial breadth, and citation behavior. For a journal to be abstracted and indexed in SciSearch from 2021 onward means that every article it publishes is now woven into the global web of citation data that powers literature searches, systematic reviews, bibliometric analyses, and institutional assessments.

The consequences of that inclusion ripple outward quickly. A paper on a novel nanoparticle formulation or a new approach to oral drug absorption that might once have been seen primarily by the journal’s existing readership can now surface in the reference lists, alerts, and search results of researchers on every continent. Citations accumulate, and those citations feed directly into the journal’s Impact Factor, the most scrutinized single number in scholarly publishing. The 2022 Impact Factor of 5.5 for the Journal of Pharmaceutical Investigation reflects the average number of times articles published in the preceding two years were cited during 2022. Crossing the threshold into double-digit percentile territory in a crowded category is a meaningful achievement that reflects both the quality of the work the journal publishes and the engagement of the community that reads it.

The ranking attached to that Impact Factor deserves particular attention. The Journal of Pharmaceutical Investigation’s position of 48 out of 278 journals in the Pharmacology and Pharmacy category places it in the Q1 band, the top quartile of its discipline. Quartile rankings divide a category’s journals into four groups by citation performance, and Q1 status is frequently used by funding agencies, hiring committees, and universities as shorthand for excellence. In a field as broad and competitive as pharmacology and pharmacy, which spans everything from medicinal chemistry and pharmacokinetics to clinical pharmacy practice and health economics, occupying the top quartile requires a journal to be cited at rates that exceed roughly three-quarters of its peers. That is a demanding standard in a category where established, decades-old titles compete for the same citations.

Understanding why these metrics matter requires a look at how scientific visibility actually works. Researchers cannot read everything; the volume of pharmaceutical literature published each year runs to hundreds of thousands of articles. Search engines, recommendation tools, and citation databases act as filters, and journals that are indexed in the major databases are dramatically more likely to appear in those filters. An article that is not indexed is, for practical purposes, invisible to much of the global research community, no matter how rigorous its methods or how important its findings. Indexing in SciSearch therefore functions as a guarantee of discoverability, ensuring that the pharmaceutical research published in the journal can be found by the translational scientists, formulation chemists, regulatory affairs professionals, and clinicians who might build on it.

For authors, the practical implications are considerable. Early-career scientists choosing where to submit their work weigh the visibility of a journal heavily, because citations shape careers: grant applications, promotions, and tenure decisions all lean on publication records. A journal with a 5.5 Impact Factor and a Q1 ranking offers a persuasive combination of reach and prestige, particularly for interdisciplinary work in drug delivery, pharmacokinetics, and pharmaceutical technology where the readership spans pharmacy, chemistry, materials science, and medicine. Authors also gain the assurance that their work will be captured in institutional repositories, reported in faculty citation profiles, and counted in national research assessments that draw on Web of Science data.

For readers and research institutions, indexing and citation metrics serve a different but equally important function: they act as quality signals in an environment of information overload. Libraries use indexing status and citation performance to make subscription decisions, allocating finite budgets toward journals that their communities actually use and cite. Systematic reviewers and meta-analysts, whose syntheses of the literature inform clinical guidelines and regulatory decisions, depend on indexed databases to ensure their searches are comprehensive. When a journal is reliably indexed, reviewers can trust that its content will be captured in their search strategies, reducing the risk that important evidence is overlooked. In pharmaceutical research, where a missed finding can influence drug development decisions with billions of dollars and patient safety at stake, that reliability carries real weight.

The journal’s trajectory also illustrates broader dynamics in scholarly publishing. Impact Factors are recalculated annually and can shift with changes in a field’s citation culture, the timing of highly cited articles, and the growth of a journal’s readership. A journal that earns a strong Impact Factor often enters a virtuous cycle: greater visibility attracts stronger submissions, stronger submissions attract more citations, and more citations reinforce the metrics that drew authors in the first place. Entering the Science Citation Index Expanded in 2021 gave the Journal of Pharmaceutical Investigation access to exactly this cycle, and the 2022 figure of 5.5 provides early evidence that the cycle is turning favorably. Sustaining that position will depend on continued editorial rigor, timely publication, and the ability to anticipate where pharmaceutical science is heading next.

Pharmaceutical investigation itself is a field in the midst of remarkable ferment, and the research indexed under this journal’s banner reflects that energy. Drug delivery science is being reshaped by lipid nanoparticles, antibody-drug conjugates, and mRNA platforms whose importance the pandemic made unmistakable. Pharmacokinetic modeling increasingly incorporates artificial intelligence and physiologically based simulation to predict human outcomes from preclinical data. Formulation scientists are tackling biologics, cell therapies, and nucleic acid medicines that defy the traditional tools of the discipline. A Q1-ranked journal embedded in this landscape functions as a convergence point, drawing together the pharmacists, chemical engineers, clinicians, and data scientists whose combined work determines whether laboratory discoveries become medicines on pharmacy shelves.

As the Journal of Pharmaceutical Investigation continues its indexed run, its citation record will be watched not only by its editors and authors but by the wider community that relies on bibliometric indicators to navigate an expanding literature. The 2022 Impact Factor of 5.5 and the Q1 rank of 48 out of 278 in Pharmacology and Pharmacy establish a clear benchmark, and they assure researchers that work published in the journal will be counted, cited, and seen. In a scientific ecosystem where discoverability can determine whether a finding shapes a new therapy or fades unread, the combination of rigorous peer review, inclusion in the Science Citation Index Expanded, and strong citation performance represents the difference between publishing and truly communicating. For pharmaceutical science, one of the most consequential research endeavors of the age, that distinction matters.

Subject of Research: Abstracting, indexing, and citation performance of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, impact factor, Science Citation Index Expanded, SciSearch, Web of Science, pharmacology, pharmacy, Q1 journal, citation metrics, drug delivery, scholarly publishing, pharmaceutical sciences

To understand why this matters, it helps to unpack what indexing in the Science Citation Index Expanded actually means. The Science Citation Index Expanded is one of the core citation databases maintained within the Web of Science, the citation ecosystem originally built on Eugene Garfield’s pioneering work at the Institute for Scientific Information. Inclusion is not automatic. Journals seeking coverage undergo a rigorous evaluation process in which publishers submit documentation of editorial standards, peer review practices, editorial board composition, publication ethics policies, and the international diversity of authorship. Clarivate’s editorial development team assesses whether the journal meets the quality thresholds for foundational coverage and whether its citation performance justifies admission. Being accepted into SciSearch in 2021 signaled that the Journal of Pharmaceutical Investigation had cleared one of the most demanding quality gates in scholarly publishing, a gate that thousands of journals worldwide never pass.

Indexing, in turn, is the precondition for the metric that has become the lingua franca of journal evaluation: the Impact Factor. Calculated annually by Clarivate from the Journal Citation Reports, the Impact Factor for a given year counts the number of citations received in that year by items published in the journal during the two preceding years, divided by the number of citable items published in those same two years. A value of 5.5 for 2022 therefore means that, on average, each citable article published in the journal during 2020 and 2021 was cited 5.5 times in 2022. Because the journal entered SciSearch in 2021, this figure reflects a relatively early citation window, which makes the performance even more striking. New entrants to the citation index typically take several years to accumulate visibility, so a first-quartile placement so soon after admission suggests an unusually rapid adoption by the research community.

The quartile classification adds another layer of meaning. Clarivate assigns journals to categories, and within each category journals are ranked by their Impact Factor and divided into quartiles, with Q1 representing the top 25 percent of titles. The Pharmacology and Pharmacy category is one of the largest and most competitive in the entire Web of Science taxonomy, encompassing 278 journals that range from mega-journals of translational medicine to highly specialized publications in toxicology, drug metabolism, and clinical pharmacy. Ranking 48th in that field places the Journal of Pharmaceutical Investigation firmly within the upper tier of pharmacological publishing, alongside far more established titles with decades of citation history. For authors weighing where to submit manuscripts, quartile placement often carries practical consequences, because funding agencies, promotion committees, and doctoral programs in many countries explicitly require publication in Q1 journals.

The journal’s subject scope helps explain its rising citation profile. Pharmaceutical investigation as a discipline sits at the crossroads of pharmaceutics, biopharmaceutics, drug delivery, pharmacokinetics, and formulation science, and it increasingly absorbs techniques from nanotechnology, materials science, and computational modeling. Research published under this umbrella includes studies of controlled-release systems, lipid-based carriers, polymeric nanoparticles, dissolution testing, bioavailability enhancement, and the physicochemical characterization of novel dosage forms. In recent years the field has been swept up in broader currents reshaping the pharmaceutical sciences, including the explosion of interest in mRNA delivery platforms, the refinement of long-acting injectable formulations, and the application of machine learning to formulation optimization. Journals positioned at the center of these currents tend to attract high citations, because their articles serve as methodological references for large and fast-moving research communities.

The journal in question is published by Springer, one of the major international scientific publishers, and the pharmaceutical sciences have long been a strategic area for the company’s portfolio. The relationship between publisher and index provider is central to the economics of modern scholarly communication. Publishers invest in editorial infrastructure, peer review management, digital preservation, and dissemination platforms, while citation index providers aggregate the resulting literature into evaluative frameworks that institutions use to allocate resources. The feedback loop can be powerful. Indexing increases discoverability through Web of Science searches, discoverability drives downloads and citations, and citations raise the Impact Factor, which in turn attracts stronger submissions from researchers seeking maximum visibility for their work. The journal’s 2022 numbers suggest that this flywheel has begun to turn decisively.

It is worth pausing on how rapidly scholarly metrics themselves have evolved, because the Impact Factor, despite its ubiquity, is a blunt instrument. Critics have long noted that the two-year citation window disadvantages slow-moving fields, that citation distributions within journals are heavily skewed so that a small fraction of papers accounts for most citations, and that aggregate scores can be gamed through editorial strategies such as publishing review articles, which attract citations at a higher rate than primary research. The San Francisco Declaration on Research Assessment, signed by thousands of journals and institutions, urges evaluators to look past journal-level metrics to the actual content and quality of individual papers. Yet the practical reality in much of the world, particularly in Asia, Europe, and Latin America, is that Impact Factors and quartiles remain embedded in grant applications, hiring decisions, and national research assessment exercises. Against that backdrop, a journal’s climb into Q1 translates directly into the career incentives of working scientists.

The pharmaceutical sciences occupy a distinctive position in this evaluative landscape because the field straddles academia and industry. Research on drug delivery and formulation frequently progresses from laboratory bench to clinical application, and the intellectual property and commercial stakes involved mean that citation patterns differ from those in purely academic disciplines. Industry scientists read and cite the pharmaceutical technology literature when designing development programs, and regulatory science considerations, such as bioequivalence standards and dissolution specifications, generate steady citation demand for foundational methodology papers. A Q1 journal in this space therefore functions not only as an academic outlet but as a shared reference point connecting university labs, contract research organizations, generic drug manufacturers, and innovator pharmaceutical companies across dozens of countries.

The timeline of the journal’s ascent is also instructive for understanding how new journals break through in a crowded market. Acceptance into SciSearch in 2021 followed the standard probationary logic of the Web of Science: emerging journals receive partial coverage initially, typically tracking newly published content, and their citation records build as indexed material accumulates. Within a single full cycle the journal achieved an Impact Factor of 5.5 and a category rank of 48 of 278, performance that many long-established titles would consider strong. This acceleration is characteristic of the current era, in which digital distribution, social media amplification, and global submission pipelines allow a well-edited journal to reach its audience far faster than was possible in the print-dominated decades when citation reputations took a generation to form.

For observers of scientific publishing, the broader lesson is that the map of influential journals is not fixed. The Pharmacology and Pharmacy category continues to expand, the tools for evaluating research continue to evolve, and the competition for high-quality manuscripts intensifies as publishers launch new open-access titles and established journals adjust their strategies. The Journal of Pharmaceutical Investigation’s 2022 standing, with an Impact Factor of 5.5 and a first-quartile ranking among 278 pharmacology journals, demonstrates how indexing prestige, editorial focus, and community engagement combine to reshape that map. Whether the journal can sustain and improve its position in future Journal Citation Reports will depend on the same factors that drive all scholarly success: the quality and novelty of the science it publishes, the rigor of its peer review, and its ability to serve as an indispensable resource for the researchers advancing drug development worldwide.

Subject of Research: Indexing and citation performance of the Journal of Pharmaceutical Investigation in the Web of Science Pharmacology and Pharmacy category

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Impact Factor, Science Citation Index Expanded, Web of Science, pharmacology, pharmacy, quartile ranking, citation metrics, drug delivery, pharmaceutical sciences, Springer, Q1 journal

Abstracting and indexing may sound like a dry administrative exercise, but for working scientists it is the infrastructure that determines whether their work is ever seen. When a journal is indexed in a major citation database, every published article gains a standardized record: a structured abstract, author affiliations, subject headings, bibliographic metadata and, critically, a persistent link that other researchers can follow from a search result to the full text. Without that record, even excellent research risks becoming invisible, buried in a journal that search engines and literature reviews rarely surface. Indexing is therefore the mechanism by which a journal’s content enters the bloodstream of scientific communication.

Science Citation Index Expanded, maintained within the Web of Science ecosystem, is one of the most selective and widely recognized of these databases. Journals admitted to the index undergo evaluation of their editorial rigor, publishing standards, peer-review processes, international authorship and citation behavior. Inclusion since 2021 means that all content published by the Journal of Pharmaceutical Investigation from that point onward is systematically captured, allowing citation links to accumulate year by year. This is a prerequisite for any journal that hopes to receive a Journal Impact Factor, the most discussed single number in scholarly publishing.

The Journal Impact Factor itself is a deceptively simple calculation. In any given year, it counts the citations received in that year by items a journal published in the two preceding years, divided by the number of substantive, citable items, chiefly research articles and reviews, published in those same two years. A 2022 impact factor of 5.5 therefore reflects citations earned during 2022 by material published in 2020 and 2021. That figure indicates that, on average, each citable article from those years was cited more than five times within the measurement window, a level of citation intensity that places the journal firmly among the most influential publications in its discipline.

Just as significant as the raw score is the category ranking: 48th out of 278 journals in Pharmacology and Pharmacy. Citation density varies enormously between fields, so a raw impact factor means little until it is contextualized within a discipline. Quartile placement provides that context. A first-quartile position, corresponding to the top 25 percent of journals in the category, signals to authors, reviewers, librarians and funding bodies that the journal sits within the leading tier of venues for pharmaceutical research. It is this rank, rather than the number alone, that most often determines where researchers choose to submit their best work.

For pharmaceutical scientists, the practical consequences are concrete. A Q1 journal with a 5.5 impact factor becomes a preferred destination for studies on novel drug delivery systems, pharmacokinetics, formulation science, nanotechnology-based therapeutics and clinical investigation of new compounds. Authors gain the assurance that their papers will be read by a broad, international audience and that citations will be tracked and attributed correctly. Readers gain the assurance that the journal’s editorial standards have been vetted by an independent indexing body. Institutions, in turn, use these indicators when evaluating faculty productivity, since indexed, highly ranked publications carry more weight in hiring, promotion and grant assessments.

The timing of the indexing also matters. A journal’s early years in a citation index are typically characterized by incomplete citation trails, because it takes time for the database to record references pointing back to newly indexed content. As the 2021 entry point recedes, successive impact factor cycles will draw on an increasingly complete record of the journal’s output. This dynamic often produces a period of citation growth, as previously published articles continue to accrue citations while the denominator of citable items stabilizes. The 2022 figure of 5.5 should therefore be read not as a static endpoint but as a data point in an ongoing trajectory of the journal’s scientific footprint.

It is worth pausing on why metrics like these attract such intense attention, and also on their limits. The Journal Impact Factor was originally designed as a library-management tool, a way to help librarians decide which journals to subscribe to, not as a measure of the quality of any individual paper. A citation to an article can be positive, negative or merely incidental, and citation counts are influenced by article type, review coverage and field trends. Editors and bibliometricians have long cautioned against grading individual researchers by the impact factor of the journals in which they publish. Nevertheless, at the level of the journal as a whole, the metric remains a fast, transparent and universally understood signal of scholarly influence, and quartile rankings in particular continue to shape real decisions across the research enterprise.

Within pharmaceutical science specifically, the value of strong indexing infrastructure is amplified by the field’s translational character. Research published in these pages informs drug formulation, bioavailability enhancement, controlled-release technology, pharmacoeconomics and regulatory science, and its audience spans academic laboratories, industrial research and development groups, clinical pharmacologists and regulatory reviewers. When a study on a novel nanoparticle carrier or an improved oral delivery platform is properly abstracted and indexed, it can be retrieved by a formulator searching for prior art, by a regulatory scientist drafting a dossier or by a clinician weighing a new therapeutic approach. Each of those retrieval events is a potential citation, and each citation strengthens the record on which the journal’s ranking rests. Indexing, citation and scientific progress form a single feedback loop.

The Journal of Pharmaceutical Investigation’s combined achievement, inclusion in Science Citation Index Expanded since 2021, a 2022 Journal Impact Factor of 5.5 and a Q1 ranking of 48 out of 278 in Pharmacology and Pharmacy, therefore represents more than a publishing success. It reflects the cumulative choices of thousands of authors who selected the journal as the home for their work, the reviewers and editors who upheld its scientific standards, and the researchers worldwide whose citations now register in the databases that measure contemporary science. As the journal’s indexed archive matures, its bibliometric record will continue to evolve, and the pharmaceutical research community will be watching how that trajectory develops in the annual release of citation reports to come.

Beyond the headline numbers, the mechanics of how a journal enters and moves through the citation ecosystem deserve closer attention. Science Citation Index Expanded traces its lineage to the Citation Index for Science created in the 1960s, when bibliographers first demonstrated that references embedded in published papers could be aggregated into a searchable network of scholarly influence. That insight, that citations function as explicit acknowledgments of prior intellectual debt, remains the conceptual foundation of modern bibliometrics, and every impact factor calculated today descends from it.

The distinction between being indexed and being measured is also worth clarifying. Journals admitted to Science Citation Index Expanded receive standardized bibliographic records and become part of the citation network, but the Journal Impact Factor itself is released through a separate annual reporting process that evaluates journals after a period of consistent indexing. This staged progression explains why newly indexed journals often need several annual cycles before their metrics stabilize, and why the 2022 assessment of the Journal of Pharmaceutical Investigation represents an early but meaningful reading of its citation performance rather than a mature one.

For authors deciding where to submit, indexing status interacts with other practical considerations. Pharmaceutical research is a fast-moving field in which preprints, conference proceedings and patent literature all compete for attention, so the assurance that a journal’s records are systematically captured and cross-linked carries real weight. Standardized metadata also enables bibliometric tools to disambiguate authors with similar names, connect related datasets and track the diffusion of a finding across disciplines, functions that become increasingly important as pharmaceutical science grows more interdisciplinary, drawing on chemistry, biology, engineering and clinical medicine simultaneously.

The category in which the journal is ranked deserves note as well. Pharmacology and Pharmacy is a broad and crowded classification that encompasses basic pharmacological research, drug design, clinical therapeutics and pharmacy practice, meaning journals compete for citation attention across quite different audiences. Achieving a position within the top quartile of such a heterogeneous category suggests that the journal’s content resonates beyond a narrow specialty, attracting citations from multiple subfields rather than from a single tightly knit community. Cross-disciplinary citation of this kind is often cited by editors as a sign of durable relevance.

Finally, the broader publishing environment shapes how such metrics should be interpreted. Scholarly communication is undergoing sustained change, with open access models, alternative metrics and funder mandates altering how research is disseminated and discovered. Citation-based measures remain the most established currency of journal evaluation, but they increasingly sit alongside downloads, altmetric attention and policy citations in a fuller picture of impact. Within that evolving landscape, a journal that combines rigorous peer review, international reach and strong indexed performance is well positioned to remain a trusted venue as the standards by which science is assessed continue to develop.

Subject of Research: Abstracting and indexing of pharmaceutical research journals and citation metrics

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: abstracting and indexing, Science Citation Index Expanded, SciSearch, Journal Impact Factor, pharmacology, pharmacy, Q1 journal, citation metrics, Web of Science, pharmaceutical investigation, journal ranking, scholarly publishing